Monopar Therapeutics LLC
Developing orphan oncology drugs
This article was originally published in Start Up
Executive Summary
Monopar Therapeutics LLC is focusing on developing treatments for hard-to-treat cancer subtypes. Its lead program, huATN-658, is a humanized monoclonal antibody that targets the urokinase plasminogen activator receptor (uPAR). A protein receptor, uPAR is found on certain cancer cells, but it has little to no expression on healthy tissue; it is linked with tumor cell survival, its expression increases in high-grade and metastatic disease and it is correlated with a worse prognosis in several cancers.
You may also be interested in...
Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip
Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.
Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways